TOP STORIES
rheumatology

#EULAR2017

Wednesday 14th - Monday 19th June 2017
Rheumatoid arthritis

Certolizumab doesn’t cross the placenta

The continuation of the anti-TNF certolizumab during pregnancy may be an option for women who need their disease activity controlled because it doesn’t cross the placenta in significant concentrations, a pharmacokinetic study shows. Presenting their findings at EULAR the authors led...

The continuation of the anti-TNF certolizumab during pregnancy may be an option for women who need their disease activity controlled...
Rheumatoid arthritis

Full blown RA prevented with early treatment

Early therapeutic intervention significantly reduces the risk of RA onset in pre-RA patients, a meta analysis presented at the EULAR congress in Madrid shows. The meta-analysis of studies set out to examine the effectiveness of steroids, csDMARDs and bDMARDS on preventing...

Early therapeutic intervention significantly reduces the risk of RA onset in pre-RA patients, a meta analysis presented at the EULAR...
Rheumatoid arthritis

Stop ‘bitching and whining’ about ACR-EULAR criteria, delegates told

Most people criticising the current ACR/EULAR definition of RA remission are confused over its purpose, delegates have been told. Opening the session fifty shades of remission in RA, Professor Martin Boers from the Department of Epidemiology & Biostatistics, Amsterdam Rheumatology and Immunology Centre...

Most people criticising the current ACR/EULAR definition of RA remission are confused over its purpose, delegates have been told. Opening the...